CLINICAL TRIALS PROFILE FOR TICLOPIDINE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for TICLOPIDINE HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00004727 ↗ | Antiplatelet Therapy to Prevent Stroke in African Americans | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 4 | 1969-12-31 | The African-American Antiplatelet Stroke Prevention Study is designed to prevent recurrent strokes by administration of aspirin or ticlopidine. The study also provides community information on reducing risk of stroke and recognizing the symptoms of stroke. The study involves more than 50 participating hospitals located throughout the United States. Study medication is provided free of charge, and a transportation stipend is available for those in need. |
| NCT00069069 ↗ | E-Selectin Nasal Instillation to Prevent Secondary Stroke | Withdrawn | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 1 | 2003-10-01 | This study will determine the maximum safe dose of the experimental drug E-selectin that can be given to stroke patients. E-selectin causes white blood cells called lymphocytes to change so that they prevent clots from forming in the vessels that supply blood to the brain. The drug has been shown to be effective in animal models of stroke. This study will look at the safety of using this experimental drug in nasal instillation form in patients who have had a stroke or transient ischemic attack (TIA). Patients 45 years of age or older who have had a recent stroke or TIA (30 to 120 days before entering the study) due to a clot forming in a vessel that supplies blood to the brain may be eligible for this study. They must be taking at least one medication to prevent clots, such as coumadin, aspirin, ticlopidine, or others. Candidates will be screened with a physical and neurological examination, blood and urine tests, electrocardiogram (EKG), echocardiogram (ultrasound test of the heart), and magnetic resonance imaging (MRI) of the brain. Participants will be randomly assigned to receive E-selectin at a dose level of 5, 15, or 50 micrograms or a placebo (nasal drops with no active ingredient). They will instill a small, carefully premeasured amount (one dose) of fluid in their nose every other day for 10 days (total of 5 doses). This course of treatment will be repeated two times at 3-week intervals. Patients will be followed at 1 month and 3 months with a neurologic examination and blood and urine tests. They will be contacted by phone, fax, or email in between these two visits. |
| NCT00133003 ↗ | Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2) | Completed | Technische Universität München | Phase 4 | 2003-03-01 | The purpose of this study is to determine whether there is any additional benefit from abciximab administration during percutaneous coronary intervention in patients presenting with acute coronary syndromes after pre-treatment with 600mg of clopidogrel. |
| NCT00133003 ↗ | Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2) | Completed | Deutsches Herzzentrum Muenchen | Phase 4 | 2003-03-01 | The purpose of this study is to determine whether there is any additional benefit from abciximab administration during percutaneous coronary intervention in patients presenting with acute coronary syndromes after pre-treatment with 600mg of clopidogrel. |
| NCT00262054 ↗ | Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3) | Completed | Deutsches Herzzentrum Muenchen | Phase 4 | 2005-11-01 | The purpose of this study is to determine whether bivalirudin given during PCI is associated with better outcomes compared to un-fractionated heparin. |
| NCT00325390 ↗ | Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation | Completed | Daiichi Pharmaceuticals | Phase 3 | 2004-07-01 | To evaluate the efficasy and safety of SR25990C(loading dose:300mg, maintenance dose:75mg/day) in comparison with the standard Japanese treatment(ticlopidine) in patients with acute coronary syndrome without ST-segment elevation and planned for percutaneous coronary intervention(including stenting). |
| NCT00325390 ↗ | Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation | Completed | Sanofi | Phase 3 | 2004-07-01 | To evaluate the efficasy and safety of SR25990C(loading dose:300mg, maintenance dose:75mg/day) in comparison with the standard Japanese treatment(ticlopidine) in patients with acute coronary syndrome without ST-segment elevation and planned for percutaneous coronary intervention(including stenting). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TICLOPIDINE HYDROCHLORIDE
Condition Name
Clinical Trial Locations for TICLOPIDINE HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for TICLOPIDINE HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for TICLOPIDINE HYDROCHLORIDE
Sponsor Name
